Michigan Medicine | University of Michigan
More patients receiving meropenem-vaborbactam (n=28), compared to patients receiving BAT (n=15), for the treatment of CRE infections achieved a clinical cure at the end of therapy (64.3% vs. 33.3%, p =0.04) and test-of-cure visit (57.1% vs. 26.7%, p = 0.04) respectively. 28-day mortality was statistically similar in the patients receiving ... ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- ceftolozane tazobactam zerbaxatm michigan medicine
- antimicrobial resistance prevalence at the uks first
- auspar attachment 2 extract from the clinical evaluation
- rapid diagnostic technology to aid in identification of
- general outline for antibiotics a good study guide
- home page clinical microbiology and infection
- supplemental digital content
- michigan medicine university of michigan
- australian public assessment for ceftolozane as sulfate
Related searches
- university of michigan admissions staff
- university of michigan admission requirement
- university of michigan sat scores
- university of michigan payroll office
- university of michigan application deadline
- university of michigan act requirements
- university of michigan entrance requirements
- university of michigan transfer deadline
- university of michigan philosophy dept
- university of michigan applicant portal
- university of michigan neurology
- university of michigan hospital neurology